D Little1, C Chai-Adisaksopha1, C Hillis2, D M Witt3, M Monreal4, M A Crowther1, D M Siegal5. 1. Department of Medicine, McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada. 2. Department of Oncology, McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada. 3. Department of Pharmacotherapy, The University of Utah, 201 Presidents Circle, Salt Lake City, UT 84112, United States. 4. Department of Internal Medicine, Hospital Universitari Germans Trias I Pujol, Carretera de Canyet, s/n, Barcelona 08916, Spain. 5. Department of Medicine, McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada. Electronic address: siegald@mcmaster.ca.
Abstract
INTRODUCTION: Oral anticoagulation (OAC) is permanently discontinued in up to 50% of patients following a gastrointestinal (GI) bleed. A previous meta-analysis showed a reduced risk of thromboembolism and death, and a non-statistically significant increased risk of re-bleeding associated with resumption. We conducted an updated meta-analysis to determine the risks of recurrent GI bleeding, thromboembolism, and death in patients who resumed OAC compared to those who did not. MATERIALS AND METHODS: We searched EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials for new references from January 2014 to September 2017. Randomized controlled trials and observational studies involving adults with OAC-related GI bleeding were included. Risk of bias was assessed using the Cochrane Collaboration's ROBINS-I tool. Pooled relative risk (RR) ratios were calculated using a random-effects model. RESULTS: We identified 12 observational studies involving 3098 patients. There was an increased risk of recurrent GI bleeding (RR 1.91, 95% CI 1.47-2.48, I2 = 0%, 11 studies), and a reduced risk of thromboembolism (RR 0.30, 95% CI 0.13-0.68, I2 = 59.8%, 9 studies) and death (RR 0.51, 95% CI 0.38-0.70, I2 = 71.8%, 8 studies) in patients who resumed OAC compared to those who did not. Eleven studies were judged to be at serious risk of bias due to confounding. CONCLUSIONS: Resuming OAC after OAC-related GI bleeding appears to be associated with an increase in recurrent GI bleeding, but a reduction in thromboembolism and death. Further prospective data are needed to identify patients for whom the net clinical benefit favours OAC resumption and the optimal timing of resumption.
INTRODUCTION: Oral anticoagulation (OAC) is permanently discontinued in up to 50% of patients following a gastrointestinal (GI) bleed. A previous meta-analysis showed a reduced risk of thromboembolism and death, and a non-statistically significant increased risk of re-bleeding associated with resumption. We conducted an updated meta-analysis to determine the risks of recurrent GI bleeding, thromboembolism, and death in patients who resumed OAC compared to those who did not. MATERIALS AND METHODS: We searched EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials for new references from January 2014 to September 2017. Randomized controlled trials and observational studies involving adults with OAC-related GI bleeding were included. Risk of bias was assessed using the Cochrane Collaboration's ROBINS-I tool. Pooled relative risk (RR) ratios were calculated using a random-effects model. RESULTS: We identified 12 observational studies involving 3098 patients. There was an increased risk of recurrent GI bleeding (RR 1.91, 95% CI 1.47-2.48, I2 = 0%, 11 studies), and a reduced risk of thromboembolism (RR 0.30, 95% CI 0.13-0.68, I2 = 59.8%, 9 studies) and death (RR 0.51, 95% CI 0.38-0.70, I2 = 71.8%, 8 studies) in patients who resumed OAC compared to those who did not. Eleven studies were judged to be at serious risk of bias due to confounding. CONCLUSIONS: Resuming OAC after OAC-related GI bleeding appears to be associated with an increase in recurrent GI bleeding, but a reduction in thromboembolism and death. Further prospective data are needed to identify patients for whom the net clinical benefit favours OAC resumption and the optimal timing of resumption.
Authors: Agnieszka Kotalczyk; Michał Mazurek; Zbigniew Kalarus; Tatjana S Potpara; Gregory Y H Lip Journal: Nat Rev Cardiol Date: 2020-10-27 Impact factor: 32.419
Authors: Behnood Bikdeli; Fares Moustafa; José Antonio Nieto; Alfred I Lee; Nuria Ruíz-Giménez; Alicia Lorenzo; Sebastian Schellong; Silvia Soler; Salvador Ortíz; Mª Del Valle Morales; Marijan Bosevski; Olga Gavín; Gregory Y H Lip; Manuel Monreal Journal: Thromb Res Date: 2022-01-14 Impact factor: 3.944
Authors: Derek H W Little; Rinku Sutradhar; Joshua O Cerasuolo; Richard Perez; James Douketis; Anne Holbrook; J Michael Paterson; Tara Gomes; Deborah M Siegal Journal: CMAJ Date: 2021-03-01 Impact factor: 8.262
Authors: Harsukh Benipal; Anne Holbrook; J Michael Paterson; James Douketis; Gary Foster; Lehana Thabane Journal: BMJ Open Date: 2020-09-22 Impact factor: 2.692